相关实验视频

Updated: Jul 21, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

针对复发性或耐火性扩散性大B细胞淋巴瘤 (DLBCL) 的成年人进行向治疗:Tafasitamab在背景下

Haifaa Abdulhaq¹, Andrew Hwang¹, Omar Mahmood¹

¹Division of Hematology/Oncology, University of California San Francisco, Fresno, CA, USA.

OncoTargets and therapy

|July 26, 2023

概括

对于复发性/耐药的扩散性大B细胞淋巴瘤,塔法西他马布-莱纳利多米德提供持久的反应. 这种疗法对于因接触或并发症而无法接受CAR T细胞治疗的患者来说是一个至关重要的替代方案.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

复发性/耐火性 (R/R) 扩散性大B细胞淋巴瘤 (DLBCL) 在历史上有不良结果.
新型疗法,包括针对CD19的药物和化学抗原受体 (CAR) T细胞疗法,改善了预后,但面临着进入障碍.
虽然CAR T细胞疗法具有变革性,但不适合所有R/R DLBCL患者.

研究的目的:

审查针对R/R DLBCL的有针对性的治疗选择.
为那些无法接受CAR T细胞治疗的患者强调替代疗法.
为了突出Tafasitamab-lenalidomide在R/R DLBCL中的疗效.

主要方法:

对R/R DLBCL目前已批准和最近研究的向疗法的审查.
专注于作为CAR T细胞疗法的替代品的治疗方法.
对Tafasitamab-lenalidomide的疗效和反应持续时间的分析.

主要成果:

塔法西他马布 (抗CD19抗体) 加上莱纳利多米德在R/R DLBCL患者中显示出显著的疗效和持久的反应,这些患者无法接受自身干细胞移植 (ASCT).
塔法西他马布-莱纳利多米德和其他向药物 (抗体-药物合物,双特异性抗体) 为患有有限的CAR T细胞接入或疾病进展快速的患者提供了关键的选择.
这些替代方案解决了与CAR T细胞治疗相关的局限性,包括并发症和制造延迟.

结论:

塔法西他马布-莱纳利多米德是R/R DLBCL患者的关键治疗选择,不适合CAR T细胞治疗.
向疗法为大量患者提供可行和有效的治疗策略.
审查强调了在管理R/R DLBCL时可访问的替代品的重要性.

关键词:

DLBCL DLBCL 是一个字母.莱纳利多胺的使用方法塔法西塔马巴巴是什么意思

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.